Candidate disorders for BCL-XL inhibition could be polycythemia vera, the very rare acute erythroid leukemia (AML M6), essential thrombocytosis and acute megakaryocytic leukemia (AML M7), and perhaps even minimally differentiated acute myeloblastic leukemia (AML M0). The gene discussed is BCL2L1; the disease is acquired polycythemia vera.